Bris­tol My­ers, 2sev­en­ty roll out full Abec­ma da­ta in ear­li­er-stage can­cer

Bris­tol My­ers Squibb and 2sev­en­ty bio teased a top-line win for their BC­MA-tar­get­ing CAR-T Abec­ma in ear­li­er stages of mul­ti­ple myelo­ma back in Au­gust. Now …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER